Regenerative Neuroimmunology
Short description
Stroke affects about 12 million people worldwide annually and leads to long-lasting or permanent disability. No efficient therapy is currently available, except for the removal of the occluding blood clot during the first hours after ischemic stroke.
Our research team showed that intranasal treatment with a C3a peptide accelerates functional recovery after experimental stroke. The treatment is effective even when started a full week after stroke, which means that intranasal C3a could help to reduce neurological impairments and improve the quality of life for the majority of, if not all, stroke survivors. Our goal is to translate this novel treatment to clinical stroke care.
Selected publications
Stokowska, A., Aswendt, M., Žucha, D., et al.
J Clin Invest. 2023;133:e162253.
Escartin, C., Galea, E., Lakatos, A., et al.
Nat Neurosci. 2021;24: 312-325.
Stokowska, A., Atkins, A.L., Moran, J., et al.
Brain 2017;140: 353-369.
Moran, J., Stokowska, A., Walker, F.R., et al.
Exp Neurol. 2017;290:74-84.
Bunketorp Käll, L., Lundgren-Nilsson, Å., Samuelsson, H., et al.
Stroke 2017;48:1916-1924.
Shinjyo, N., De Pablo, Y., Pekny, M., Pekna, M.
Mol Neurobiol. 2016;53:3076-3087.
Pekny, M., Pekna, M.
Physiol Rev.2014;94:1077-1098.
Järlestedt, K., Rousset, C.I., Ståhlberg, A., et al.
FASEB J. 2013;27:3797-3804.
Shinjyo, N., Ståhlberg, A., Dragunow, M.,
Stem Cells 2009;27:2824-2832.
EMBO J. 2006;25:1364-1374.
Group members
Principal Investigator:
Marcela Pekna, MD, PhD, professor
Doctoral student:
Maria Mode, MD
Researchers:
Anna Stokowska, PhD
Alumni:
Yixian Li, Stephanie Lohmann, Andrea Pozo-Rodrigalvarez, Men Su, Javier Moran Suarez, Noriko Shinjyo, Michaela Pascoe, Alison Atkins, Marta Perez Alcazar, Max Albert Hietala, Rosanna Olsen, Linda Persson, Yalda Rahpeymai Bogestål
